Biodesix Inc (BDSX)vsNatera Inc (NTRA)
BDSX
Biodesix Inc
$23.50
+6.33%
HEALTHCARE · Cap: $221.51M
NTRA
Natera Inc
$322.10
+21.37%
HEALTHCARE · Cap: $38.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 2503% more annual revenue ($2.50B vs $96.10M). NTRA leads profitability with a -9.1% profit margin vs -33.3%. NTRA earns a higher WallStSmart Score of 31/100 (F).
BDSX
Avoid29
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.9%
Fair Value
$8.93
Current Price
$23.50
$14.57 premium
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.3% year-over-year
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 26.1x book value
ROE of -349.9% — below average capital efficiency
0.0% earnings growth
Weak financial health signals
Trading at 25.9x book value
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : BDSX
The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.84 is elevated, increasing financial risk.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
NTRA carries more volatility with a beta of 1.50 — expect wider price swings.
BDSX is growing revenue faster at 42.3% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NTRA scores higher overall (31/100 vs 29/100) and 38.8% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?